ARIAD Announces Publication of Ponatinib Phase 1 Clinical Trial Results in the …
ARIAD Announces Publication of Ponatinib Phase 1 Clinical Trial Results in the …
Filed under: drug treatment news articles
The article is accompanied by an editorial by John M. Goldman, D.M., F.R.C.P. of the Department of Haematology, Imperial College London (Pages 2148-49). The Phase 1 dose-escalation study of ponatinib enrolled 81 … ARIAD's approach to structure-based …
Read more on The Herald | HeraldOnline.com
Survey Of The Pancreatic Cancer Drug Market With Celgene's Abraxane In Focus
Filed under: drug treatment news articles
Earlier this year, in August, the FDA approved Xtandi (enzalutamide)- to be marketed by Medivation (MDVN) for the treatment of metastatic castration-resistant prostate cancer. Per a FDA news release from September 27, 2012, Stivarga, a multi-kinase …
Read more on Seeking Alpha
Study Finds KRAS Testing in Metastatic CRC Saves Money, but Questions Value …
Filed under: drug treatment news articles
Although implementing genetic testing for KRAS and BRAF to guide anti-EGFR treatment can save payors around $ 8,000 per patient compared to administering these drugs without PGx testing, the study results indicate that the cheapest strategy would be to …
Read more on GenomeWeb